Melanoma Matters14 Loka 2024

Ep 06: CheckMate 238

Summary

In this conversation, Sapna Patel and James Larkin discuss the Checkmate 238 landmark study on adjuvant therapy for melanoma. They touch on various topics, including food choices, pets, and the study design. They highlight the importance of considering the heterogeneity and tempo of melanoma in treatment decisions. They also discuss the challenges of conducting dedicated trials for mucosal and acral melanoma subtypes. Overall, the Checkmate 238 study established the use of adjuvant anti-PD-1 therapy and has long-term follow-up data.

Keywords

melanoma, adjuvant therapy, Checkmate 238, study design, heterogeneity, tempo, mucosal melanoma, acral melanoma

Takeaways

Consider the heterogeneity and tempo of melanoma when making treatment decisions.
Dedicated trials are needed to determine the efficacy of adjuvant therapy for mucosal and acral melanoma subtypes.
The Checkmate 238 study established the use of adjuvant anti-PD-1 therapy for melanoma.
Long-term follow-up data is important for assessing the efficacy and safety of adjuvant therapy.

Sound Bites

"Unconditionally loyal. Yeah, if only men were like this, right? Yeah, just kidding."

"If you compare the EORTC study with the Checkmate238 study, does NIVO have an OS benefit?"

"Patient selection for treatment is really, really important."

Chapters

00:00 Introduction and Quick Fires

03:12 The Checkmate 238 Landmark Study

08:17 Patient Selection and Challenges in Mucosal and Acral Melanoma

13:05 The Importance of Tempo and Risk of Relapse

16:17 The Need for Dedicated Trials in Mucosal and Acral Melanoma

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(87)

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min

Live from ASCO 2026: a preview

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more

1 Kesä 6min

Ep 81: IGNYTE trial (RP1 + nivo)

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...

13 Helmi 32min

Ep 80: 2025 Holiday Special

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...

30 Joulu 202535min

Ep 79: coBRIM, COMBI-d 5-year follow-up

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...

29 Joulu 202536min

Ep 78 TRAILER: MEK inhibitor trials

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

29 Joulu 20251min

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib...

29 Joulu 202537min